The Myanmar Pharmaceutical Industrial Enterprise(MPIE) will establish a pharmaceutical complex to produce medicines compliant with international pharmaceutical standards. Detailed scope of works includes:

• site preparation; and installation of utilities such as roads and infrastructure, water supply, and electricity;

• Phase 1: establishment of an active pharmaceutical ingredient plant, oncology plant, training center, residential building, and distribution center;

• Phase 2: establishment of a tablet and capsule plant, Small Volume Parenteral Solution and Large Volume Parenteral Solution Plant;

• license application at Food and Drug Administration (FDA) after construction; and

• commercial operation upon obtaining FDA license.

Electricity required for the project can be obtained through a 66-kilovolt (kV) line from the Hlawga power station about 15 miles from the project site. Treatment systems will be installed for wastewater generated from the industrial zone.

The production plants will produce pharmaceutical raw materials, cancer drugs, tablets, capsules, injections, infusions and medical devices.

The project aims to meet domestic demand, produce medicines that have not yet been produced locally, improve pharmaceutical production technology, invite foreign international pharmaceuticals interested to do business in the country, create job opportunities, and efficiently use of vacant land owned by MPIE.

The project is proposed to be undertaken in collaboration with the private sector to reduce reliance on national budget allocation, promote the private sector, address scarcity of skilled workers in state-owned enterprises, and deal with complicated policies and long procedures. MPIE will contribute state-owned land.